Abstract
In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(8;21), t(15;17), t(16;16) and inv(16) is present in a sample obtained from the subject; wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML
Original language | English |
---|---|
Patent number | 514/34 |
IPC | C12Q1/68; A61K31/4184; A61K31/502; A61K45/06 |
Priority date | 17/09/14 |
Publication status | Published - 21 Jul 2016 |
Keywords
- biomarkers
- leukemia
- PARP inhibitor
- DNA damage